Bamco Inc. NY trimmed its position in shares of argenex SE (NASDAQ:ARGX – Free Report) by 8.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 153,719 shares of the company’s stock after selling 13,975 shares during the period. Bamco Inc. NY’s holdings in argenex were worth $129,270,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds have also modified their holdings of the company. Capital World Investors raised its holdings in shares of argenex by 0.4% during the 3rd quarter. Capital World Investors now owns 1,959,504 shares of the company’s stock worth $1,445,113,000 after acquiring an additional 8,422 shares in the last quarter. M&T Bank Corp raised its holdings in shares of argenex by 20,977.7% during the 4th quarter. M&T Bank Corp now owns 778,610 shares of the company’s stock worth $654,772,000 after acquiring an additional 774,916 shares in the last quarter. Wellington Management Group LLP raised its holdings in shares of argenex by 80.1% during the 3rd quarter. Wellington Management Group LLP now owns 729,986 shares of the company’s stock worth $538,408,000 after acquiring an additional 324,653 shares in the last quarter. Morgan Stanley raised its holdings in shares of argenex by 19.2% during the 4th quarter. Morgan Stanley now owns 518,852 shares of the company’s stock worth $436,331,000 after acquiring an additional 83,746 shares in the last quarter. Finally, Sands Capital Management LLC raised its holdings in shares of argenex by 2,046.6% during the 4th quarter. Sands Capital Management LLC now owns 356,870 shares of the company’s stock worth $300,110,000 after acquiring an additional 340,245 shares in the last quarter. 60.32% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
Several analysts recently weighed in on ARGX shares. Glj Research upgraded argenex to a “strong-buy” rating in a report on Friday, April 3rd. Wells Fargo & Company increased their price target on argenex from $1,260.00 to $1,291.00 and gave the company an “overweight” rating in a report on Monday, June 1st. Zacks Research upgraded argenex from a “strong sell” rating to a “hold” rating in a report on Friday, February 20th. Robert W. Baird increased their price target on argenex from $858.00 to $867.00 and gave the company a “neutral” rating in a report on Friday, February 27th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of argenex in a report on Monday, April 20th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, argenex currently has an average rating of “Moderate Buy” and a consensus target price of $1,019.50.
argenex Stock Performance
NASDAQ:ARGX opened at $892.26 on Thursday. The stock’s fifty day moving average is $820.36 and its 200 day moving average is $810.81. argenex SE has a fifty-two week low of $510.05 and a fifty-two week high of $934.62. The firm has a market capitalization of $55.49 billion, a PE ratio of 39.73, a PEG ratio of 1.34 and a beta of 0.47.
argenex (NASDAQ:ARGX – Get Free Report) last announced its quarterly earnings data on Tuesday, March 31st. The company reported $5.52 EPS for the quarter. The company had revenue of $1.31 billion for the quarter. argenex had a return on equity of 44.37% and a net margin of 31.31%. Equities analysts forecast that argenex SE will post 26.19 EPS for the current year.
argenex Company Profile
argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.
The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.
Featured Articles
- Five stocks we like better than argenex
- Cheap Thrills: Why These 3 Entertainment Stocks Are Soaring
- CoreWeave Insider Sales Look Big, But Should Investors Worry?
- Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves
- Meta and Cloud Computing: Real Potential, or a Shot in the Dark?
Want to see what other hedge funds are holding ARGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for argenex SE (NASDAQ:ARGX – Free Report).
Receive News & Ratings for argenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenex and related companies with MarketBeat.com's FREE daily email newsletter.
